EMERYVILLE, Calif. / Oct 16, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three investor conferences during the month of November. 2025 Truist Securities BioPharma Symposium, November 6 at the Lotte New York Palace Hotel . Matt Foehr, Chief Executive Officer, will participate in one-on-one meetings with investors on Thursday, November 6 th . Stifel 2025... Read More

EMERYVILLE, Calif. / Oct 14, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2025, after the close of the U.S. financial markets on Tuesday, November 4, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter 2025... Read More

EMERYVILLE, Calif. / Sep 02, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will participate at the H.C. Wainwright 27 th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. Management will be available for one-on-one meetings on Tuesday, September 9 th with investors registered for the event. Investors interested in scheduling a... Read More

EMERYVILLE, Calif. / Aug 25, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / Aug 06, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. “Our business is performing very well as we continued our momentum in partner additions in the second quarter, reaching 100 active partners. This... Read More

EMERYVILLE, Calif. / Jul 16, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Wednesday, August 6, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss second quarter 2025 financial... Read More

xPloration Maximizes Impact for OmniAb’s Partners through Efficient and Precise Mining of Immunized Antibody Repertoires EMERYVILLE, Calif. / May 13, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced its participation in the 21 st Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the Omni Hotel. Earlier today, the company showcased case studies utilizing xPloration, a... Read More

High-Throughput Single B-Cell Screening Platform Now Available for Purchase by OmniAb’s Partners for Use in Their Own Laboratories EMERYVILLE, Calif. / May 08, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration instrument to significantly enhance their capabilities in antibody discovery and... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / May 08, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. “We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline... Read More

ZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ: VACH, "Voyager"), announced today a co-discovery alliance with OmniAb, Inc. (NASDAQ: OABI, “OmniAb”) for the development of a novel bispecific antibody drug conjugate (“bsADC”) program targeting solid tumors.... Read More

EMERYVILLE, Calif. / May 01, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences over the coming weeks. H.C. Wainwright 1 st Annual Royalty Company Virtual Conference, May 13. Management will participate in a fireside chat and a panel discussion on Tuesday, May 13 th . H.C. Wainwright 3 rd Annual BioConnect Investor Conference at Nasdaq, May 20... Read More

Philip Gotwals, Ph.D. and Steve Crouse bring strategic and operational experience in business development and global tools and technology EMERYVILLE, Calif. / Apr 21, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six... Read More

EMERYVILLE, Calif. / Apr 14, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss first quarter 2025 financial results and... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / Mar 18, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. “2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage... Read More

EMERYVILLE, Calif. / Feb 24, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss fourth quarter financial... Read More

EMERYVILLE, Calif. / Feb 03, 2025 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45 th Annual Health Care Conference, March 3-5 at the Boston Marriott Copley Place. Management will be presenting a corporate overview on Tuesday, March 4 th at 2:30 p.m. Eastern time and will be holding one-on-one meetings with... Read More

Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub ™ , a bioinformatics tools platform EMERYVILLE, Calif. / Dec 16, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company’s technologies were delivered at the 2024 Antibody Engineering & Therapeutics Conference (AETC) underway in San Diego. In a presentation titled... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / Nov 12, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates. “We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our... Read More

EMERYVILLE, Calif. / Oct 30, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of November. Stifel 2024 Healthcare Conference, November 18-19 at the Lotte New York Palace Hotel . Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Tuesday, November 19 th . Jefferies London... Read More

EMERYVILLE, Calif. / Oct 22, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on Tuesday, November 12, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss third quarter financial... Read More

EMERYVILLE, Calif. / Aug 26, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of September. H.C. Wainwright 26 th Annual Global Investment Conference, September 9-11 at the Lotte New York Palace Hotel . Management will deliver a corporate presentation on Tuesday, September 10 th at 2:30 p.m. Eastern Time and will hold... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / Aug 08, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. “Second quarter results were in-line with our expectations and support our view of the full year. We advanced our business by adding new... Read More

EMERYVILLE, Calif. / Jul 25, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial markets on Thursday, August 8, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss financial results and business... Read More

Engineered chickens producing single domain antibodies (sdAbs) provided the scientific foundation for OmnidAb ™ , the Company’s novel transgenic chicken platform launched in 2023 that generates fully human and stabilized sdAbs EMERYVILLE, Calif. / Jun 03, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced the... Read More

EMERYVILLE, Calif. / May 20, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City. Management will be presenting a corporate overview on Wednesday, June 5 th at 8:00 a.m. Eastern time and will be holding one-on-one meetings with investors. A live and archived... Read More

Technical synergies between xPloration, OmniFlic ® , OmniClic ® and OmniDeep ® enable new bispecific antibody discovery workflows for OmniAb’s partners EMERYVILLE, Calif. / May 15, 2024 / Business Wire / OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20 th Annual PEGS Boston – The Essential Protein &... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / May 09, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates. “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base. We added three new... Read More

EMERYVILLE, Calif. / May 01, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences during the month of May. RBC Capital Markets Global Healthcare Conference, May 14-15 at the InterContinental Barclay Hotel in New York City . Management will participate in a fireside chat on Wednesday, May 15 th at 11:30 a.m. Eastern time and will hold one-on-one... Read More

EMERYVILLE, Calif. / Apr 22, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Thursday, May 9, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss financial results and business updates... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / Mar 20, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates. “2023 was a year of significant expansion of OmniAb's partnership base and pipeline programs as we continued to execute against our plan, while... Read More

EMERYVILLE, Calif. / Feb 26, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Wednesday, March 20, 2024 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss financial results and... Read More

EMERYVILLE, Calif. / Feb 20, 2024 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in March. TD Cowen 44th Annual Healthcare Conference, March 4-6, 2024, at the Marriott Copley Place in Boston, MA . Management will participate in a fireside chat on Monday, March 4 th at 11:10 a.m. Eastern time and will be available for one-on-one meetings... Read More

Introduces the functionality and benefits of the first and only transgenic chicken producing single-domain antibodies to antibody industry thought leaders and research scientists from around the world EMERYVILLE, Calif. / Dec 14, 2023 / Business Wire / OmniAb, Inc. (Nasdaq: OABI) announces the presentation of new scientific... Read More

Webcast and event slides available here EMERYVILLE, Calif. / Nov 09, 2023 / Business Wire / OmniAb, Inc. (Nasdaq: OABI) held its first Research & Technology virtual event earlier today, during which members of the management team reviewed the Company’s technology offerings and highlighted the launch of Omni dAb, the industry’s... Read More

Webcast including Research & Technology Event begins at 11:00 a.m. Eastern time today EMERYVILLE, Calif. / Nov 09, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates. “Our business momentum has continued with the recent addition of three new partners including another global pharma... Read More

EMERYVILLE, Calif. / Nov 02, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in November. Stifel 2023 Healthcare Conference, November 14-15, 2023 at the Lotte New York Palace Hotel in New York City. Management will participate in a fireside chat on Wednesday, November 15 th at 8:00 a.m. Eastern time and will be available for... Read More

EMERYVILLE, Calif. / Nov 01, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb’s Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five... Read More

November 9 th webcast to include a review of third quarter 2023 financial results EMERYVILLE, Calif. / Oct 31, 2023 / Business Wire / OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its Research & Technology virtual event to be held on Thursday, November 9 th beginning at 11:00 a.m. Eastern time. The two-hour event will include an update on the company’s technology offerings, a review of third quarter financial results,... Read More

Webcast to include an update on latest technology offerings and third quarter 2023 financial results EMERYVILLE, Calif. / Oct 12, 2023 / Business Wire / OmniAb, Inc. (Nasdaq: OABI) today announced it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time. The event is expected to last approximately two hours and will include a review of the company’s latest technology... Read More

EMERYVILLE, Calif. / Sep 05, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two upcoming investor conferences in September. H.C. Wainwright 25 th Annual Global Investment Conference, September 11-13, 2023 at the Lotte New York Palace Hotel in New York City. Management will deliver a company presentation on Tuesday, September 12 th at 9:00 a.m. Eastern time and will... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / Aug 10, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates. “Our business continued to grow and perform well during the second quarter with advancements in business development and progress across partner... Read More

EMERYVILLE, Calif. / Aug 07, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) announces that Director Sunil Patel passed away suddenly last week. The Board of Directors and leadership of OmniAb extend their deepest condolences to those who loved and cared for Sunil and express their gratitude for Sunil’s many contributions to OmniAb. Sunil Patel was appointed to OmniAb’s Board in November 2022 when OmniAb was spun-out of... Read More

EMERYVILLE, Calif. / Jul 31, 2023 / Business Wire / OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three and six months ended June 30, 2023 after the close of the U.S. financial markets on Thursday, August 10, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss financial results and business... Read More

Suite of in silico tools leverages Company’s Biological Intelligence ™ and large proprietary multi-species antibody databases to enhance the rapid identification of therapeutic candidates with optimal profiles EMERYVILLE, Calif. / May 17, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) announced the launch of OmniDeep ™ at the 19 th Annual PEGS Boston Conference and Expo: The Essential Protein Engineering & Cell Therapy... Read More

Conference Call with Slides Begins at 8:30 a.m. Eastern Time Today EMERYVILLE, Calif. / May 11, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates. “Our first quarter performance is a strong start to the year. We reached 301 active programs, with 27 in clinical development or approved for... Read More

EMERYVILLE, Calif. / May 01, 2023 / Business Wire / OmniAb, Inc. (Nasdaq: OABI) will report financial results for the three months ended March 31, 2023 before the open of the U.S. financial markets on Thursday, May 11, 2023 and will hold a conference call that same day beginning at 8:30 a.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss financial results and business updates... Read More

EMERYVILLE, Calif. / Apr 25, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five upcoming investor conferences in May. H.C. Wainwright BioConnect Investor Conference at NASDAQ, May 2, 2023 at Nasdaq World Headquarters, New York City. Management will be participating in a fireside chat on Tuesday, May 2 nd at 9:30 a.m. Eastern time and will be hosting one-on-one... Read More

Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today EMERYVILLE, Calif. / Mar 30, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates. “Following the closing of the spin-off and business combination transactions last November, OmniAb is well-positioned for continued growth by... Read More

EMERYVILLE, Calif. / Feb 07, 2023 / Business Wire / OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in three upcoming investor conferences. SVB Securities Global Biopharma Conference, February 14-16, 2023. Management will be participating in a virtual fireside chat on Wednesday, February 15 th at 11:20 a.m. Eastern time and will be hosting one-on-one virtual meetings with investors. Cowen 43... Read More

Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq EMERYVILLE, Calif., November 01, 2022--(BUSINESS WIRE)-- OmniAb, Inc. (NASDAQ: OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and the subsequent business combination with Avista Public Acquisition... Read More